Study Group: Baclofen Prescribers for Spasticity (US)
Council Members in this Study Group: 62
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Walter Carlini
Neurologist
Medford Neurological Clinic, Inc.
Walter Carlini, MD, PhD, is a General Neurologist at Medford Neurological Clinic in Oregon. His clinical interests include stroke, epilepsy, migraine, dementia, movement disorders, and multiple sclerosis. Dr. Carlini has expertise in clinical neurophysiology...
Daniel WynnDirector of Clinical Research
CONSULTANTS IN NEUROLOGY LTDDaniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple...
Luc JasminAttending Neurosurgeon and a Research Scientist
CEDARS-SINAI MEDICAL CENTERLuc Jasmin, MD, PhD, is an Attending Neurosurgeon and Research Scientist at Cedars Sinai Medical Center in Los Angeles. Dr. Jasmin is involved in a surgical practice and research centered on the treatment of pain and spinal disorders. His clinical work...
- Michael Brennan
Owner
Michael J Brennan, MDMichael Brennan, MD, is the Chief Medical Officer and Owner of The Pain Center of Fairfield in Connecticut. He is a nationally recognized leader in the field of pain management as well as cancer related disabilities and lymph edema. Dr. Brennan has served...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
TRPs as Analgesic Drug Targets: Using HC-030031 to Probe the Role of TRPA1
September 28, 2009
The 3rd Annual Pain Therapeutics Summit | click.bsftransmit1.com
Transient receptor potential cation channel, subfamily A, member 1 (TRPA1) is a cold receptor, somewhat the opposite of the capsaicin receptor (TRPV1), which is a heat receptor. TRPA1 is a chemosensor and it has an abundance of agonists, exogenous (cigarette smoke, etc...) and endogenous (prostaglandins, etc…). All neurons that express TRPA1 also express TRPV1. Stimulating TRPA1 causes pain. Hydra Biosciences is developing TRPA1 antagonists (receptor blocker) to block pain and inflammation.
-
TRPV1 Agonists: 500 Years in Development
September 28, 2009
The 3rd Annual Pain Therapeutics Summit | click.bsftransmit1.com
Qutenza is a flexible film that wraps on the skin and leads to a rapid release of 8% capsaicin. Possible applications: OA, Post-herpetic neuralgia, HIV neuropathy, and diabetic neuropathy. The results show efficacy in both post-herpetic neuralgia and HIV neuropathy as determine by 30% decrease in pain. More trials are being presently conducted. NeurogesX is developing a liquid form is that is works in a much shorter time (5 min instead of the current 30 to 60 min).
-
Antagonists: Are They Too Hot to Handle?
September 28, 2009
The 3rd Annual Pain Therapeutics Summit | click.bsftransmit1.com
Merck TRPV1 Antagonists MK-2295: Results of clinical studies and reasons why it will not make it to market MK-2295 was administered to normal individuals for 14 days. The investigator tested for heat sensitivity by applying a heat probe to the skin or the subjects having taken MK-2295 or placebo. They also immersed their hands in hot water (48 degree C) or asked them to drink hot water. The results were impressive with the subjects taking MK-2295 displaying a raised threshold to heat. The problem is that often they did do not find unpleasant temperatures around 48 degree C.
-
Responsive vs unresponsive depressive patients have similar electrode sites
September 7, 2009
Based on an association between successful and unsuccessful clinical response, the authors present stereotaxic coordinates, allowing standardization of the implantation site.The post-implantation analysis position of the intracerebral quadripolar electrodes was analyzed in twenty patients. Eleven out of 20 patients achieved a significant reduction of their depression scores at 1 year. The responder's electrodes were only slightly more ventral by 1-2 mm. See J Neurosurg (on line) / May 29, 2009.
-
Fampridine-SR -- anxiously awaited new MS therapeutic
June 2, 2009
Analysis by: Daniel Wynn, Director of Clinical Research,Acorda’s Fampridine-SR Gets Priority Review | phoenix.corporate-ir.net
A major unmet need in the treatment of Multiple Sclerosis is a medication to increase walking ability. Since disease modifying therapies have only been available for 16 years, MS starts at a mean age of 29, and the disease has only a minimal effect at shortening lifespan, the majority of MS patients presently have progressive forms of MS. Ten percent have primary progressive disease, progressive from the onset, and others, start with relapsing remitting MS, and progress after approximately 15 years to progressive illness. In the early years of progressive MS, patients loose the ability to walk, hence the prior motto of the National MS Society, "MS, the great crippler of young adults." FAMPRIDINE SR IS THE FIRST MEDICATION FOUND TO IMPROVE MS PATIENTS ABILITY TO WALK. Standard disease modifying agents, the interferons (Avonex, Betaseron, Rebif), Copaxone and Tysabri, decrease relapse rate and may slow progression, however do not improve one's ability to walk.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
- Consultancy, Healthcare-Focused
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Owner
- Director
- President
- Assistant Professor